Episode 56. Management of Newly Diagnosed CML with Dr. Hagop Kantarjian
Blood Cancer Talks · Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed:
1. ASC4FIRST RCT: Asciminib in newly diagnosed CML.
https://pubmed.ncbi.nlm.nih.gov/38820078/
2. 5-year follow-up of ENESTnd RCT (nilotinib):
https://pubmed.ncbi.nlm.nih.gov/26837842/
3. 10-year follow-up of ENESTnd RCT (nilotinib):
https://pubmed.ncbi.nlm.nih.gov/33414482/
4. 10-year follow-up of CML-IV RCT (imatinib):
https://pubmed.ncbi.nlm.nih.gov/25676422/
5. MD Anderson data on low-dose dasatinib (50 mg):
https://pubmed.ncbi.nlm.nih.gov/36054032/
https://pubmed.ncbi.nlm.nih.gov/31553487/
6. CML: 2025 update on diagnosis, therapy, and monitoring:
https://pubmed.ncbi.nlm.nih.gov/39093014/